lundi 16 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· February 2, 2026

Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3

View original at globenewswire.com
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3 Dans l’étude de phase…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • There is currently no approved treatment for the neurological manifestations of GD3

    80% confidence
  • Venglustat was generally well tolerated with no new safety signals compared to previous studies

    80% confidence
  • Venglustat achieved equivalent performance to enzyme replacement therapy on non-neurological criteria including spleen volume, liver volume, and hemoglobin levels

    80% confidence
  • Venglustat demonstrated statistically significant improvements in neurological symptoms (p=0.007) compared to enzyme replacement therapy at week 52

    80% confidence
  • These results underscore Sanofi's commitment to rare disease research and desire to offer new perspectives to people living with these conditions

    80% confidence
  • A daily pill could make a considerable difference for Gaucher disease patients facing neurological challenges

    80% confidence
  • PERIDOT study showed pain reduction in both study arms and did not meet the primary endpoint

    80% confidence

Data points we hold from this source

Sanofi · rare disease experience40 years
Communiqué de presse : Le venglustat de Sanofi a atteint tous les critères d'évaluation principaux dans une étude de phase 3 sur la maladie de Gaucher de type 3: Source | Via News | fr.via.news